- Home
- VINP vs ORIC Comparison
VINP vs ORIC Comparison
Compare VINP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VINP
- ORIC
- Stock Information
- Founded
- VINP 2009
- ORIC 2014
- Country
- VINP Brazil
- ORIC United States
- Employees
- VINP N/A
- ORIC N/A
- Industry
- VINP Investment Managers
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- VINP Finance
- ORIC Health Care
- Exchange
- VINP Nasdaq
- ORIC Nasdaq
- Market Cap
- VINP 593.2M
- ORIC 362.9M
- IPO Year
- VINP 2021
- ORIC 2020
- Fundamental
- Price
- VINP $9.77
- ORIC $10.50
- Analyst Decision
- VINP Strong Buy
- ORIC Strong Buy
- Analyst Count
- VINP 2
- ORIC 8
- Target Price
- VINP $13.25
- ORIC $18.83
- AVG Volume (30 Days)
- VINP 55.8K
- ORIC 1.1M
- Earning Date
- VINP 08-06-2025
- ORIC 08-11-2025
- Dividend Yield
- VINP 6.65%
- ORIC N/A
- EPS Growth
- VINP N/A
- ORIC N/A
- EPS
- VINP 0.38
- ORIC N/A
- Revenue
- VINP $126,696,258.00
- ORIC N/A
- Revenue This Year
- VINP $70.28
- ORIC N/A
- Revenue Next Year
- VINP $14.37
- ORIC N/A
- P/E Ratio
- VINP $25.66
- ORIC N/A
- Revenue Growth
- VINP 57.51
- ORIC N/A
- 52 Week Low
- VINP $8.66
- ORIC $3.90
- 52 Week High
- VINP $11.62
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- VINP 54.87
- ORIC 71.20
- Support Level
- VINP $9.43
- ORIC $9.80
- Resistance Level
- VINP $9.94
- ORIC $11.19
- Average True Range (ATR)
- VINP 0.25
- ORIC 0.61
- MACD
- VINP 0.03
- ORIC -0.04
- Stochastic Oscillator
- VINP 70.65
- ORIC 83.33
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Equity, Equities, Real Assets, Credit, Global IP&S, and Corporate Advisory. The company's majority of its revenue comes from the Private Equity segment, which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.